| Literature DB >> 34084777 |
Anderson José1, Anne E Holland2,3, Jessyca P R Selman4, Cristiane Oliveira de Camargo4, Diogo Simões Fonseca5, Rodrigo A Athanazio6, Samia Z Rached6, Alberto Cukier6, Rafael Stelmach6, Simone Dal Corso4.
Abstract
AIM: To investigate the short- and long-term effects of home-based pulmonary rehabilitation (HBPR) on functional capacity, quality of life, peripheral muscle strength, dyspnoea and daily physical activity in people with bronchiectasis.Entities:
Year: 2021 PMID: 34084777 PMCID: PMC8165366 DOI: 10.1183/23120541.00021-2021
Source DB: PubMed Journal: ERJ Open Res ISSN: 2312-0541
FIGURE 1Consolidated standards of reporting trials participant disposition. HBPR: home-based pulmonary rehabilitation; PR: pulmonary rehabilitation.
Baseline characteristics of participants
| 30 | 33 | ||
| 18 (60) | 16 (48.5) | 0.360 | |
| 49.27±14.10 | 44.42±16.16 | 0.209 | |
| 24.02±2.91 | 23.96±2.56 | 0.933 | |
| 2.90±0.92 | 2.48±1.03 | 0.097 | |
| Idiopathic | 15 (50) | 7 (21) | |
| Recurrent pneumonia | 6 (20) | 9 (27) | |
| Gastro-oesophageal reflux disease | 4 (13) | 1 (3) | |
| Other causes | 5 (17) | 16 (49) | |
| 0.366 | |||
| 1 | 1 (3.3) | 6 (18.2) | |
| 2 | 10 (33.3) | 11 (33.3) | |
| 3 | 11 (36.7) | 11 (33.3) | |
| 4 | 7 (23.3) | 4 (12.1) | |
| 5 | 1 (3.3) | 1 (3.0) | |
| 2.50±1.04 | 2.27±1.23 | 0.431 | |
| Mild/moderate severity | 15 (50)/15 (50) | 16 (49)/17 (51) | |
| 2.57±1.19 | 2.45±1.37 | 0.730 | |
| Mild/moderate severity | 24 (80)/6 (20) | 26 (79)/7 (21) | 0.905 |
| | 14 (46.7) | 10 (30.3) | 0.189 |
| 2.35±0.81 | 2.59±0.97 | 0.296 | |
| 68.90±20.57 | 72.30±21.89 | 0.527 | |
| 1.37±0.56 | 1.63±0.84 | 0.151 | |
| 51.21±0.56 | 55.15±27.19 | 0.535 | |
| 59.09±14.30 | 61.47±16.49 | 0.542 | |
| 433.79±145.74 | 477.40±196.88 | 0.319 | |
| 8.22±6.87 | 8.14±6.90 | 0.961 | |
| 115.92±71.74 | 141.94±93.89 | 0.230 | |
| 6045±2731 | 7340±4754 | 0.186 | |
| 26.46±12.15 | 26.52±10.76 | 0.983 |
Data are presented as n, n (%) or mean±sd, unless otherwise stated. HBPR: home-based pulmonary rehabilitation; BMI: body mass index; MRC: Medical Research Council dyspnoea scale; FACED: forced expiratory volume in 1 s (FEV1), age, chronic colonisation by Pseudomonas aeruginosa, radiological extension and dyspnoea; E-FACED: FACED criteria plus exacerbation; FVC: forced vital capacity; ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test; MIST: modified incremental step test.
Change in clinical differences from baseline to 2 months and follow-up (6 months)
| 60.94±119.79 (21.84–100.04)* | −32.39±50.63 (−80.08–10.49) | −26.97±80.15 (−65.37–11.42) | 31.55±131.74 (−13.67–78.85) | 87.91 (32.98–142.85)# | −63.94 (−129.87–1.99) | |
| 4.62±5.43 (2.88–6.35)* | −0.14±3.82 (−2.88–2.60) | 0.26±3.34 (−1.44–1.96) | 0.43±7.47 (−2.38–3.25) | 4.36 (1.93–6.79)# | −0.57 (−4.50–3.35) | |
| 66.11±87.86 (38.80–93.42)* | −32.73±54.08 (−54.30– −11.16)¶ | −15.24±40.47 (−42.02–11.54) | −3.99±28.46 (−28.45–20.47) | 81.35 (43.10–119.60)# | −28.74 (−61.35–3.88) | |
| 735.76±3114.20 (−275.40–1746.61) | −815.90±4359.73 (−2501.33–869.54) | −592.70±2032.41 (−1585.63–400.24) | −834.05±2614.79 (−2565.67–897.57) | 1328.45 (−88.72–2745.61) | −18.15 (−2398.30–2434.59) | |
| 4.90±7.63 (2.24–7.56)* | −3.06±8.67 (−6.78–0.66) | −0.82±6.09 (−3.43–1.79) | −0.24±7.19 (−4.07–3.58) | 5.72 (1.99–9.45)# | −2.82 (−8.15–2.51) | |
Data are presented as mean±sd (95% CI). HBPR: home-based pulmonary rehabilitation; ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test; MIST: modified incremental step test. *: p<0.05 versus baseline; #: p<0.05 between groups; ¶: p<0.05 versus end rehabilitation.
Change in quality of life differences from baseline to 2 months and follow-up (6 months)
| 10.30±18.05 (2.79–17.80)* | −10.11±18.78 (−18.26– −1.95)# | −1.15±20.73 (−8.66–6.36) | −1.76±15.94 (−10.39–6.86) | 11.44 (0.83–22.06)¶ | −8.34 (−20.21–3.53) | |
| 11.30±12.85 (4.84–17.76)* | −5.58±12.74 (−11.09– −0.07)# | −0.22±19.87 (−6.69–6.24) | −1.24±10.67 (−7.06–4.59) | 11.52 (2.38–20.66)¶ | −4.34 (−12.36–3.67) | |
| 0.37±15.90 (−5.85–6.59) | −11.79±16.74 (−19.18– −4.40)# | −1.00±16.29 (−7.22–5.22) | −2.24±14.81 (−10.05–5.58) | 1.37 (−7.42–10.16) | −9.55 (−20.31–1.21) | |
| 3.52±12.34 (−1.08–8.12) | −0.89±12.98 (−5.83–7.62) | −3.63±11.46 (−8.23–0.97) | −4.41±15.90 (−11.52–2.70) | 7.15 (0.65–13.65)¶ | 5.31 (−4.48–15.10) | |
| 1.26±26.41 (−7.83–10.35) | 1.68±17.82 (−7.24–10.61) | −3.41±20.28 (−12.50–5.68) | −0.06±20.53 (−9.49–9.38) | 4.67 (−8.19–17.52) | 1.74 (−11.24–14.73) | |
| −5.30±25.15 (−15.10–4.51) | 5.68±19.69 (−4.92–16.29) | −0.07±25.63 (−9.88–9.73) | −2.71±25.76 (−13.92–8.51) | −5.22 (−19.09–8.64) | 8.39 (−7.04–23.82) | |
| −2.63±17.71 (−9.05–3.79) | 9.84±18.64 (1.73–17.96)# | −1.15±15.44 (−7.57–5.26) | 8.65±15.91 (0.07–17.23)# | −1.48 (−10.56–7.59) | 1.20 (−10.62–13.01) | |
| 3.04±11.31 (−1.93–8.00) | −4.68±11.33 (−10.26–0.89) | −0.56±14.23 (−5.52–4.41) | −7.88±2.62 (−13.78– −1.99)# | 3.59 (−3.43–10.61) | 3.20 (−4.91–11.31) | |
Data are presented as mean±sd (95% CI). HBPR: home-based pulmonary rehabilitation; QoL-B: Quality of Life Questionnaire Bronchiectasis. *: p<0.05 versus baseline; #: p<0.05 versus end rehabilitation; ¶: p<0.05 between groups.